Zimmer announced plans to acquire Abbott Spine for approximately $360 million in cash (a 3.3x revenue multiple.) Zimmer says the acquisition will add innovative products to their portfolio and augment the company's R&D capabilities. Zimmer's stock was flat in midday... more
Earnings: Biomet reported its 1Q:07 earnings totaled $0.44 per share (excluding the adoption of the share-based payment) which was $0.01 more than what analysts were expecting. Revenues increased by 5% to $508 million (foreign currency had a $3 million favorable... more
Earnings: Biologics: Orthovita reported 2Q:06 product sales came in at $11.2 million, up 32% compared to 2Q:05. On a non-GAAP basis net loss for the quarter was $5.1 million, or a loss of $0.10 per share. The Company did not... more
It's all about spine this week. With NASS in full swing in Philadelphia, many companies eagerly issued press releases during the conference. Clinical: Cervical-Stim® is a post-operative cervical brace that generates a uniformed, low-level pulsed electromagnetic field (PEMF) at the... more
It's all about spine this week. With NASS in full swing in Philadelphia, many companies eagerly issued press releases during the conference. Clinical: Cervical-Stim® is a post-operative cervical brace that generates a uniformed, low-level pulsed electromagnetic field (PEMF) at the... more
Yesterday Abbott Spine announced that it invested $15 million in Replication Medical, Inc., a developer of implantable hydrogel devices intended for the treatment of degenerative spinal disc disease. Valuation data was not available even from the best of our sources,... more
Complete Archive
Reports
Dr. Gary Michelson knows his patent rights.
Medtronic made him a billionaire for it.
Knowing the rules of intellectual property is just as important for any device firm.
It's such a critical factor in firm valuations: affecting cash flow timelines, product development, partnering, and many other competitive factors.
Purchase this report for $295 »
